Corporate Overview

Alzamend Neuro™, Inc., (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments through advanced research and development. Alzamend Neuro’s™ underlying goal is to get a treatment or cure for Alzheimer’s to market at a reasonable cost as quickly as possible. Far too many suffer daily, patients and caregivers alike, from the burden created by the nation’s 6th leading cause of death and ‘most feared disease’. To date, 5.8 million Americans are suffering from AD, which directly impacts more than 16 million Americans who provide unpaid care for an estimated 18.5 billion hours, valued to be at $234 billion. In 2019, Alzheimer’s disease is estimated to cost the United States over $290 billion and could rise as high as $1.1 trillion by 2050 if no treatment or cure is found.

Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) from the research and preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend Neuro™ has licensed both a patented mutant-peptide immunotherapeutic (AL002) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (AL001) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimer’s disease. With AL001 and AL002, the Company believes that we can change that.

Join Our Newsletter